Due to its various mechanisms of action such as cell cycle arrest, Histone deacetylase inhibition, up-regulation of p21CIP1/WAF1, and downregulation of CDK2, CDK4, and CDK6 activities, GRh2 is being increasingly recognized as a highly effective and hopeful treatment for leukemia with significant anti-tumor properties and limited adverse effects (Table 1). Here, CDKN1A is linked to leukemia.